Hostname: page-component-cd9895bd7-8ctnn Total loading time: 0 Render date: 2024-12-27T03:47:01.577Z Has data issue: false hasContentIssue false
  • English
  • Français

Effects of zopiclone on quality of life in insomnia

Published online by Cambridge University Press:  16 April 2020

I Hindmarch
I Hindmarch*
Affiliation:
Human Psychopharmacology Research Unit, University of Surrey, Milford Hospital, Godalming GU7 1UF, UK
Get access

Summary

All of the components of quality of life can be altered in insomniacs because of sleep disorders themselves but theoretically also in consequence to side effects from hypnotic agents. The presented international study, carried out with a multicentre, randomised and double-blind design, investigated zopiclone effects on quality of life in insomniac patients as compared to placebo. A total of 458 patients completed the study, 231 receiving zopiclone 7.5 mg and 227 receiving placebo, with mean treatment durations of 48 and 44 days. Sleep parameters and quality of life, measured with extensive and validated scales, were assessed at baseline and at 14, 28 and 56 days after admission. Zopiclone showed hypnotic efficacy and significantly greater improvement of quality of life as compared to placebo, both at 14 days and at endpoint.

Keywords

zopiclonehypnoticinsomniaquality of life
Type
Research Article
Information
European Psychiatry , Volume 10 , Issue S3: Satellite Symposium to the AEP Congress , 1995 , pp. 91s - 94s
Copyright
Copyright © Elsevier, Paris 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Dehlin, ORundgren, ABorjesson, L, et al. Zopiclone to geriatric patients. Pharmacology 1983;27suppl 2:39–46Google ScholarPubMed
Dupuy, HJThe Psychological General Well Being Index. In: Wenger, NKMattson, MEFurger, CDElison, J eds. Assessment of quality of life in clinical trials of cardiovascular therapies. New York: Le Jacq, 1984 170–83, 353–6Google Scholar
Gill, TMFeinstein, ARA critical appraisal of the quality of quality-of-life measurements. JAMA 1994; 272: 619–26CrossRefGoogle ScholarPubMed
Goldenberg, FHindmarch, IJoyce, CRBLe Gal, MPartinen, MPilate, CZopiclone, sleep and health-related quality of life. Hum Psychopharmacol 1994; 9: 245–51CrossRefGoogle Scholar
Jenkins, CDStanton, BANiemcryck, SJRose, RMA scale for the estimation of sleep problems in clinical research. J Clin Epidemiol 1988; 41: 313–21CrossRefGoogle ScholarPubMed
Kelly, FDelahaye, CLe Gal, MQuality of Life insomnia Results of the validation studies for a specifically designed questionnaire. J Am Med Assoc SEA 1993;suppl: 21–8Google Scholar
Klimm, HDDreyfus, JFDelmotte, MZopiclone versus nitrazepam: a double blind comparative study of efficacy and tolerance in elderly patients with chronic insomnia. Sleep 1987; 10(suppl 1):73–8CrossRefGoogle ScholarPubMed
Parrott, ACHindmarch, IThe Leeds Sleep Evaluation Questionnaire. Psychopharmacology 1980; 71: 173–9CrossRefGoogle ScholarPubMed
Rombaut, NMaillard, FKelly, FHindmarch, IThe Quality of Life of Insomniacs Questionnaire (QOLI). Med Sci Res 1990; 18: 845–7Google Scholar
Walker, SRRosser, R ed. Quality of life: assessment and application. Lancaster: MTP Press, 1988Google Scholar
Submit a response

Comments

No Comments have been published for this article.